Inventiva SACA

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

04 1 2023 16:00:00 提供 Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022

03 1 2023 02:35:00 提供 Nasdaq GlobeNewswire

Combined General Meeting of January 25, 2023 - Availability of the preparatory documents

03 1 2023 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

12 12 2022 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

28 11 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces a new Director of the Board of Directors

21 11 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports 2022 Third Quarter Financial Information¹

10 11 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva provides an update on the development of cedirogant by AbbVie

31 10 2022 03:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

21 10 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports its 2022 first-half financial results and provides a corporate update

22 9 2022 02:30:02 提供 Nasdaq GlobeNewswire

Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

21 9 2022 16:40:00 提供 Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

07 9 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva Reports 2022 First-Half Financial Information¹

28 7 2022 16:00:00 提供 Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

21 7 2022 12:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

07 7 2022 16:00:00 提供 Nasdaq GlobeNewswire

Update on Inventiva's cash position and on the finance documentation with the European Investment Bank

04 7 2022 12:45:00 提供 Nasdaq GlobeNewswire

Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

16 6 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

09 6 2022 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva joins the Euronext Tech Leaders segment

07 6 2022 16:00:00 提供 Nasdaq GlobeNewswire

 Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association

03 6 2022 16:00:00 提供 Nasdaq GlobeNewswire